{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:51:29Z","timestamp":1787003489687,"version":"build-2736575974"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,8,17]],"date-time":"2017-08-17T00:00:00Z","timestamp":1502928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,8,17]],"date-time":"2017-08-17T00:00:00Z","timestamp":1502928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    There is an urgent need for the rational design of safe and effective vaccines to protect against chronic bacterial pathogens such as\n                    <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                    . Advax\u2122 is a novel adjuvant based on delta inulin microparticles that enhances immunity with a minimal inflammatory profile and has entered human trials to protect against viral pathogens. In this report we determined if Advax displays broad applicability against important human pathogens by assessing protective immunity against infection with\n                    <jats:italic>M. tuberculosis<\/jats:italic>\n                    . The fusion protein CysVac2, comprising the\n                    <jats:italic>M. tuberculosis<\/jats:italic>\n                    antigens Ag85B (Rv1886c) and CysD (Rv1285) formulated with Advax provided significant protection in the lungs of\n                    <jats:italic>M. tuberculosis<\/jats:italic>\n                    -infected mice. Protection was associated with the generation of CysVac2-specific multifunctional CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cells (IFN-\u03b3\n                    <jats:sup>+<\/jats:sup>\n                    TNF\n                    <jats:sup>+<\/jats:sup>\n                    IL-2\n                    <jats:sup>+<\/jats:sup>\n                    ). Addition to Advax of the TLR9 agonist, CpG oligonucleotide (Advax\n                    <jats:sup>CpG<\/jats:sup>\n                    ), improved both the immunogenicity and protective efficacy of CysVac2. Immunisation with CysVac2\/Advax\n                    <jats:sup>CpG<\/jats:sup>\n                    resulted in heightened release of the chemoattractants, CXCL1, CCL3, and TNF, and rapid influx of monocytes and neutrophils to the site of vaccination, with pronounced early priming of CysVac2\n                    <jats:italic>-<\/jats:italic>\n                    specific CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cells. As delta inulin adjuvants have shown an excellent safety and tolerability profile in humans, CysVac2\/Advax\n                    <jats:sup>CpG<\/jats:sup>\n                    is a strong candidate for further preclinical evaluation for progression to human trials.\n                  <\/jats:p>","DOI":"10.1038\/s41598-017-09119-y","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T07:41:53Z","timestamp":1502437313000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Delta inulin-based adjuvants promote the generation of polyfunctional CD4+ T cell responses and protection against Mycobacterium tuberculosis infection"],"prefix":"10.1038","volume":"7","author":[{"given":"Claudio","family":"Counoupas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayathri","family":"Nagalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warwick J.","family":"Britton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai","family":"Petrovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Triccas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,17]]},"reference":[{"key":"9119_CR1","unstructured":"World Health Organization, Global tuberculosis report 2016. http:\/\/www.who.int\/tb\/publications\/global_report\/ (2016)."},{"key":"9119_CR2","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S2213-2600(14)70033-5","volume":"2","author":"SH Kaufmann","year":"2014","unstructured":"Kaufmann, S. H. et al. Progress in tuberculosis vaccine development and host-directed therapies-a state of the art review. The lancet. Respiratory medicine \n                           2, 301\u2013320 (2014).","journal-title":"The lancet. Respiratory medicine"},{"key":"9119_CR3","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nri2510","volume":"9","author":"P Marrack","year":"2009","unstructured":"Marrack, P., McKee, A. S. & Munks, M. W. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol \n                           9, 287\u2013293 (2009).","journal-title":"Nat Rev Immunol"},{"key":"9119_CR4","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/ilar.46.3.280","volume":"46","author":"HF Stills Jr.","year":"2005","unstructured":"Stills, H. F. Jr. Adjuvants and antibody production: dispelling the myths associated with Freund\u2019s complete and other adjuvants. ILAR J \n                           46, 280\u2013293 (2005).","journal-title":"ILAR J"},{"key":"9119_CR5","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1097\/QAD.0000000000000343","volume":"28","author":"EG Thacher","year":"2014","unstructured":"Thacher, E. G. et al. Safety and immunogenicity of the M72\/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I\/II, randomized trial. AIDS \n                           28, 1769\u20131781 (2014).","journal-title":"AIDS"},{"key":"9119_CR6","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.4049\/jimmunol.1102696","volume":"188","author":"SL Baldwin","year":"2012","unstructured":"Baldwin, S. L. et al. The importance of adjuvant formulation in the development of a tuberculosis vaccine. J Immunol \n                           188, 2189\u20132197 (2012).","journal-title":"J Immunol"},{"key":"9119_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003116","volume":"3","author":"EM Agger","year":"2008","unstructured":"Agger, E. M. et al. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS One \n                           3, e3116 (2008).","journal-title":"PLoS One"},{"key":"9119_CR8","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1016\/j.vaccine.2010.02.094","volume":"28","author":"JT van Dissel","year":"2010","unstructured":"van Dissel, J. T. et al. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers. Vaccine \n                           28, 3571\u20133581 (2010).","journal-title":"Vaccine"},{"key":"9119_CR9","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1093\/glycob\/cwq201","volume":"21","author":"PD Cooper","year":"2011","unstructured":"Cooper, P. D. & Petrovsky, N. Delta inulin: a novel, immunologically active, stable packing structure comprising beta-D-[2 ->1] poly(fructo-furanosyl) alpha-D-glucose polymers. Glycobiology \n                           21, 595\u2013606 (2011).","journal-title":"Glycobiology"},{"key":"9119_CR10","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1099\/vir.0.019190-0","volume":"91","author":"M Lobigs","year":"2010","unstructured":"Lobigs, M. et al. An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses. J Gen Virol \n                           91, 1407\u20131417 (2010).","journal-title":"J Gen Virol"},{"key":"9119_CR11","doi-asserted-by":"publisher","first-page":"4395","DOI":"10.1128\/JVI.03144-12","volume":"87","author":"M Larena","year":"2013","unstructured":"Larena, M., Prow, N., Hall, R., Petrovsky, N. & Lobigs, M. JE-ADVAX vaccine protection against Japanese encephalitis mediated by memory B cells in the absence of CD8+ T cells and pre-exposure neutralizing antibody. Journal of Virology \n                           87, 4395\u20134402 (2013).","journal-title":"Journal of Virology"},{"key":"9119_CR12","doi-asserted-by":"publisher","first-page":"10324","DOI":"10.1128\/JVI.00480-13","volume":"87","author":"N Petrovsky","year":"2013","unstructured":"Petrovsky, N. et al. An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody. J Virol \n                           87, 10324\u201310333 (2013).","journal-title":"J Virol"},{"key":"9119_CR13","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/j.vaccine.2012.12.077","volume":"31","author":"F Saade","year":"2013","unstructured":"Saade, F., Honda-Okubo, Y., Trec, S. & Petrovsky, N. A novel hepatitis B vaccine containing Advax, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing. Vaccine \n                           31, 1999\u20132007 (2013).","journal-title":"Vaccine"},{"key":"9119_CR14","doi-asserted-by":"publisher","first-page":"5373","DOI":"10.1016\/j.vaccine.2012.06.021","volume":"30","author":"Y Honda-Okubo","year":"2012","unstructured":"Honda-Okubo, Y., Saade, F. & Petrovsky, N. Advax, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses. Vaccine \n                           30, 5373\u20135381 (2012).","journal-title":"Vaccine"},{"key":"9119_CR15","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1099\/vir.0.023242-0","volume":"92","author":"AD Cristillo","year":"2011","unstructured":"Cristillo, A. D. et al. Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations. J Gen Virol \n                           92, 128\u2013140 (2011).","journal-title":"J Gen Virol"},{"key":"9119_CR16","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/978-1-4939-3387-7_14","volume":"1403","author":"C McPherson","year":"2016","unstructured":"McPherson, C. et al. Development of a SARS coronavirus vaccine from recombinant spike protein plus delta inulin adjuvant. Methods Mol Biol \n                           1403, 269\u2013284 (2016).","journal-title":"Methods Mol Biol"},{"key":"9119_CR17","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.vaccine.2015.01.062","volume":"33","author":"E Rodriguez-Del Rio","year":"2015","unstructured":"Rodriguez-Del Rio, E. et al. A gold glyco-nanoparticle carrying a Listeriolysin O peptide and formulated with Advax delta inulin adjuvant induces robust T-cell protection against listeria infection. Vaccine \n                           33, 1465\u20131473 (2015).","journal-title":"Vaccine"},{"key":"9119_CR18","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1128\/CVI.00019-14","volume":"21","author":"B Feinen","year":"2014","unstructured":"Feinen, B., Petrovsky, N., Verma, A. & Merkel, T. J. Advax-adjuvanted recombinant protective antigen provides protection against inhalational anthrax that is further enhanced by addition of murabutide adjuvant. Clin Vaccine Immunol \n                           21, 580\u2013586 (2014).","journal-title":"Clin Vaccine Immunol"},{"key":"9119_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/srep28912","volume":"6","author":"H Davtyan","year":"2016","unstructured":"Davtyan, H. et al. Alzheimer\u2019s disease Advax(CpG)- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Abeta pathological molecules. Sci Rep \n                           6, 28912 (2016).","journal-title":"Sci Rep"},{"key":"9119_CR20","doi-asserted-by":"publisher","first-page":"5407","DOI":"10.1016\/j.vaccine.2012.06.009","volume":"30","author":"DL Gordon","year":"2012","unstructured":"Gordon, D. L. et al. Randomized clinical trial of immunogenicity and safety of a recombinant H1N1\/2009 pandemic influenza vaccine containing Advax polysaccharide adjuvant. Vaccine \n                           30, 5407\u20135416 (2012).","journal-title":"Vaccine"},{"key":"9119_CR21","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1016\/j.vaccine.2014.09.034","volume":"32","author":"D Gordon","year":"2014","unstructured":"Gordon, D., Kelley, P., Heinzel, S., Cooper, P. & Petrovsky, N. Immunogenicity and safety of Advax, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study. Vaccine \n                           32, 6469\u20136477 (2014).","journal-title":"Vaccine"},{"key":"9119_CR22","doi-asserted-by":"crossref","first-page":"P158","DOI":"10.1186\/1939-4551-6-S1-P158","volume":"6","author":"R Heddle","year":"2013","unstructured":"Heddle, R., Russo, P., Petrovsky, N., Hanna, R. & Smith, A. Immunotherapy \u2013 2076. A controlled study of delta inulin-adjuvanted honey bee venom immunotherapy. World Allergy Organ J \n                           6, P158\u2013P158 (2013).","journal-title":"World Allergy Organ J"},{"key":"9119_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/npjvaccines.2016.12","volume":"1","author":"C Counoupas","year":"2016","unstructured":"Counoupas, C. et al. Mycobacterium tuberculosis components expressed during chronic infection of the lung contribute to long-term control of pulmonary tuberculosis in mice. Npj Vaccines \n                           1, 16012 (2016).","journal-title":"Npj Vaccines"},{"key":"9119_CR24","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.vaccine.2012.10.069","volume":"31","author":"X Chen","year":"2012","unstructured":"Chen, X., Pravetoni, M., Bhayana, B., Pentel, P. R. & Wu, M. X. High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants. Vaccine \n                           31, 159\u2013164 (2012).","journal-title":"Vaccine"},{"key":"9119_CR25","doi-asserted-by":"publisher","first-page":"4221","DOI":"10.4049\/jimmunol.1302569","volume":"192","author":"W Cui","year":"2014","unstructured":"Cui, W. et al. TLR4 ligands lipopolysaccharide and monophosphoryl lipid a differentially regulate effector and memory CD8+ T Cell differentiation. Journal of immunology \n                           192, 4221\u20134232 (2014).","journal-title":"Journal of immunology"},{"key":"9119_CR26","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1084\/jem.20101824","volume":"208","author":"N Sumaria","year":"2011","unstructured":"Sumaria, N. et al. Cutaneous immunosurveillance by self-renewing dermal gammadelta T cells. J Exp Med \n                           208, 505\u2013518 (2011).","journal-title":"J Exp Med"},{"key":"9119_CR27","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.immuni.2013.08.007","volume":"39","author":"C Jakubzick","year":"2013","unstructured":"Jakubzick, C. et al. Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes. Immunity \n                           39, 599\u2013610 (2013).","journal-title":"Immunity"},{"key":"9119_CR28","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/j.0818-9641.2004.01272.x","volume":"82","author":"N Petrovsky","year":"2004","unstructured":"Petrovsky, N. & Aguilar, J. C. Vaccine adjuvants: current state and future trends. Immunol Cell Biol \n                           82, 488\u2013496 (2004).","journal-title":"Immunol Cell Biol"},{"key":"9119_CR29","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","volume":"33","author":"RL Coffman","year":"2010","unstructured":"Coffman, R. L., Sher, A. & Seder, R. A. Vaccine adjuvants: putting innate immunity to work. Immunity \n                           33, 492\u2013503 (2010).","journal-title":"Immunity"},{"key":"9119_CR30","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(08)61036-3","volume":"372","author":"DF Hoft","year":"2008","unstructured":"Hoft, D. F. Tuberculosis vaccine development: goals, immunological design, and evaluation. Lancet \n                           372, 164\u2013175 (2008).","journal-title":"Lancet"},{"key":"9119_CR31","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1016\/j.vaccine.2016.05.071","volume":"34","author":"DL Gordon","year":"2016","unstructured":"Gordon, D. L. et al. Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax delta inulin adjuvant. Vaccine \n                           34, 3780\u20133786 (2016).","journal-title":"Vaccine"},{"key":"9119_CR32","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nm.2285","volume":"17","author":"C Aagaard","year":"2011","unstructured":"Aagaard, C. et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med \n                           17, 189\u2013194 (2011).","journal-title":"Nat Med"},{"key":"9119_CR33","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001094","volume":"2","author":"S Bertholet","year":"2010","unstructured":"Bertholet, S. et al. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med \n                           2, 53ra74 (2010).","journal-title":"Sci Transl Med"},{"key":"9119_CR34","doi-asserted-by":"publisher","first-page":"7618","DOI":"10.4049\/jimmunol.172.12.7618","volume":"172","author":"YA Skeiky","year":"2004","unstructured":"Skeiky, Y. A. et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol \n                           172, 7618\u20137628 (2004).","journal-title":"J Immunol"},{"key":"9119_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/srep19570","volume":"6","author":"NP Knudsen","year":"2016","unstructured":"Knudsen, N. P. et al. Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens. Sci Rep \n                           6, 19570 (2016).","journal-title":"Sci Rep"},{"key":"9119_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083884","volume":"9","author":"MT Orr","year":"2014","unstructured":"Orr, M. T. et al. A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93. PLoS One \n                           9, e83884 (2014).","journal-title":"PLoS One"},{"key":"9119_CR37","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1128\/JVI.02980-14","volume":"89","author":"Y Honda-Okubo","year":"2015","unstructured":"Honda-Okubo, Y. et al. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. J Virol \n                           89, 2995\u20133007 (2015).","journal-title":"J Virol"},{"key":"9119_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13567-014-0130-7","volume":"45","author":"H Bielefeldt-Ohmann","year":"2014","unstructured":"Bielefeldt-Ohmann, H. et al. Safety and immunogenicity of a delta inulin-adjuvanted inactivated Japanese encephalitis virus vaccine in pregnant mares and foals. Vet Res \n                           45, 130 (2014).","journal-title":"Vet Res"},{"key":"9119_CR39","doi-asserted-by":"publisher","first-page":"6242","DOI":"10.1016\/j.vaccine.2011.06.078","volume":"29","author":"RC Layton","year":"2011","unstructured":"Layton, R. C. et al. Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets. Vaccine \n                           29, 6242\u20136251 (2011).","journal-title":"Vaccine"},{"key":"9119_CR40","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1128\/IAI.72.3.1608-1617.2004","volume":"72","author":"L Holten-Andersen","year":"2004","unstructured":"Holten-Andersen, L., Doherty, T. M., Korsholm, K. S. & Andersen, P. Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect Immun \n                           72, 1608\u20131617 (2004).","journal-title":"Infect Immun"},{"key":"9119_CR41","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nm1592","volume":"13","author":"PA Darrah","year":"2007","unstructured":"Darrah, P. A. et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med \n                           13, 843\u2013850 (2007).","journal-title":"Nat Med"},{"key":"9119_CR42","doi-asserted-by":"publisher","first-page":"8047","DOI":"10.4049\/jimmunol.0801592","volume":"182","author":"T Lindenstrom","year":"2009","unstructured":"Lindenstrom, T. et al. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol \n                           182, 8047\u20138055 (2009).","journal-title":"J Immunol"},{"key":"9119_CR43","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nri2274","volume":"8","author":"RA Seder","year":"2008","unstructured":"Seder, R. A., Darrah, P. A. & Roederer, M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol \n                           8, 247\u2013258 (2008).","journal-title":"Nat Rev Immunol"},{"key":"9119_CR44","doi-asserted-by":"publisher","first-page":"6311","DOI":"10.4049\/jimmunol.1300248","volume":"190","author":"T Lindenstrom","year":"2013","unstructured":"Lindenstrom, T., Knudsen, N. P., Agger, E. M. & Andersen, P. Control of chronic Mycobacterium tuberculosis infection by CD4 KLRG1- IL-2-secreting central memory cells. J Immunol \n                           190, 6311\u20136319 (2013).","journal-title":"J Immunol"},{"key":"9119_CR45","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","volume":"381","author":"MD Tameris","year":"2013","unstructured":"Tameris, M. D. et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet \n                           381, 1021\u20131028 (2013).","journal-title":"Lancet"},{"key":"9119_CR46","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1164\/rccm.201003-0334OC","volume":"182","author":"BM Kagina","year":"2010","unstructured":"Kagina, B. M. et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination of newborns. Am J Respir Crit Care Med \n                           182, 1073\u20131079 (2010).","journal-title":"Am J Respir Crit Care Med"},{"key":"9119_CR47","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1093\/infdis\/jir592","volume":"204","author":"C Desel","year":"2011","unstructured":"Desel, C. et al. Recombinant BCG DeltaureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses. J Infect Dis \n                           204, 1573\u20131584 (2011).","journal-title":"J Infect Dis"},{"key":"9119_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004099","volume":"10","author":"R Gopal","year":"2014","unstructured":"Gopal, R. et al. Unexpected role for IL-17 in protective immunity against hypervirulent Mycobacterium tuberculosis HN878 infection. PLoS Pathog \n                           10, e1004099 (2014).","journal-title":"PLoS Pathog"},{"key":"9119_CR49","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1084\/jem.20100265","volume":"207","author":"A Cruz","year":"2010","unstructured":"Cruz, A. et al. Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis. J Exp Med \n                           207, 1609\u20131616 (2010).","journal-title":"J Exp Med"},{"key":"9119_CR50","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/j.vaccine.2010.12.090","volume":"29","author":"S Calabro","year":"2011","unstructured":"Calabro, S. et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine \n                           29, 1812\u20131823 (2011).","journal-title":"Vaccine"},{"key":"9119_CR51","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1365-2567.2009.03164.x","volume":"129","author":"KS Korsholm","year":"2010","unstructured":"Korsholm, K. S., Petersen, R. V., Agger, E. M. & Andersen, P. T-helper 1 and T-helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of the early inflammatory response at the site of injection. Immunology \n                           129, 75\u201386 (2010).","journal-title":"Immunology"},{"key":"9119_CR52","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jconrel.2009.10.022","volume":"142","author":"M Henriksen-Lacey","year":"2010","unstructured":"Henriksen-Lacey, M. et al. Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen. Journal of controlled release: official journal of the Controlled Release Society \n                           142, 180\u2013186 (2010).","journal-title":"Journal of controlled release: official journal of the Controlled Release Society"},{"key":"9119_CR53","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/imr.12217","volume":"262","author":"S Srivastava","year":"2014","unstructured":"Srivastava, S., Ernst, J. D. & Desvignes, L. Beyond macrophages: the diversity of mononuclear cells in tuberculosis. Immunol Rev \n                           262, 179\u2013192 (2014).","journal-title":"Immunol Rev"},{"key":"9119_CR54","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.4049\/jimmunol.1001289","volume":"185","author":"CW Yang","year":"2010","unstructured":"Yang, C. W., Strong, B. S., Miller, M. J. & Unanue, E. R. Neutrophils influence the level of antigen presentation during the immune response to protein antigens in adjuvants. J Immunol \n                           185, 2927\u20132934 (2010).","journal-title":"J Immunol"},{"key":"9119_CR55","doi-asserted-by":"publisher","first-page":"5402","DOI":"10.4049\/jimmunol.180.8.5402","volume":"180","author":"A Seubert","year":"2008","unstructured":"Seubert, A., Monaci, E., Pizza, M., O\u2019Hagan, D. T. & Wack, A. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol \n                           180, 5402\u20135412 (2008).","journal-title":"J Immunol"},{"key":"9119_CR56","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.4049\/jimmunol.179.4.2509","volume":"179","author":"AJ Wolf","year":"2007","unstructured":"Wolf, A. J. et al. Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo. J Immunol \n                           179, 2509\u20132519 (2007).","journal-title":"J Immunol"},{"key":"9119_CR57","doi-asserted-by":"publisher","first-page":"4828","DOI":"10.4049\/jimmunol.1103183","volume":"188","author":"AT Kamath","year":"2012","unstructured":"Kamath, A. T. et al. Synchronization of dendritic cell activation and antigen exposure is required for the induction of Th1\/Th17 responses. J Immunol \n                           188, 4828\u20134837 (2012).","journal-title":"J Immunol"},{"key":"9119_CR58","doi-asserted-by":"publisher","first-page":"5920","DOI":"10.1016\/j.vaccine.2015.09.030","volume":"33","author":"N Petrovsky","year":"2015","unstructured":"Petrovsky, N. & Cooper, P. D. Advax, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety. Vaccine \n                           33, 5920\u20135926 (2015).","journal-title":"Vaccine"},{"key":"9119_CR59","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/nprot.2011.438","volume":"7","author":"JL Li","year":"2012","unstructured":"Li, J. L. et al. Intravital multiphoton imaging of immune responses in the mouse ear skin. Nat Protoc \n                           7, 221\u2013234 (2012).","journal-title":"Nat Protoc"},{"key":"9119_CR60","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/eji.201444954","volume":"45","author":"M Florido","year":"2015","unstructured":"Florido, M. et al. Epitope-specific CD4+, but not CD8+, T-cell responses induced by recombinant influenza A viruses protect against Mycobacterium tuberculosis infection. Eur J Immunol \n                           45, 780\u2013793 (2015).","journal-title":"Eur J Immunol"},{"key":"9119_CR61","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1093\/intimm\/dxh170","volume":"16","author":"T Tamura","year":"2004","unstructured":"Tamura, T. et al. The role of antigenic peptide in CD4+ T helper phenotype development in a T cell receptor transgenic model. Int Immunol \n                           16, 1691\u20131699 (2004).","journal-title":"Int Immunol"},{"key":"9119_CR62","doi-asserted-by":"publisher","first-page":"7172","DOI":"10.4049\/jimmunol.0801694","volume":"182","author":"AA Ryan","year":"2009","unstructured":"Ryan, A. A. et al. Antigen load governs the differential priming of CD8 T cells in response to the bacille Calmette Guerin vaccine or Mycobacterium tuberculosis infection. Journal of immunology \n                           182, 7172\u20137177 (2009).","journal-title":"Journal of immunology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-09119-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-09119-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-09119-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T03:45:51Z","timestamp":1671767151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-09119-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,17]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["9119"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-09119-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,17]]},"assertion":[{"value":"6 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"8582"}}